Table 4.
Cancer Hazard Ratios (HRs) by statin use using time dependent models.
| Endometrial cancer | Ovarian cancer | |||
|---|---|---|---|---|
|
|
|
|||
| Age-adjusted HR | Multivariable adjusted HR | Age-adjusted HR | Multivariable Adjusted HR | |
| Statin | ||||
| No | 1.00 | 1.00 | 1.00 | 1.00 |
| Yes | 0.95 (0.80–1.13) |
0.91 (0.76–1.08) |
1.28 (1.04–1.59) |
1.30 (1.04–1.62) |
| Statin type | ||||
| No use | 1.00 | 1.00 | 1.00 | 1.00 |
| Atorvastatin | 0.95 (0.74–1.22) |
0.92 (0.71–1.19) |
1.14 (0.81–1.60) |
1.13 (0.79–1.60) |
| Fluvastatin | 0.83 (0.44–1.54) |
0.76 (0.40–1.47) |
1.49 (0.80–2.80) |
1.31 (0.65–2.65) |
| Lovastatin | 0.67 (0.38–1.18) |
0.64 (0.36–1.13) |
1.11 (0.59–2.08) |
1.07 (0.55–2.07) |
| Pravastatin | 0.96 (0.64–1.43) |
0.97 (0.65–1.45) |
1.73 (1.13–2.64) |
1.89 (1.24–2.88) |
| Simvastatin | 1.12 (0.84–1.48) |
1.04 (0.78–1.39) |
1.22 (0.83–1.79) |
1.26 (0.85–1.88) |
| Statin category | ||||
| No use | 1.00 | 1.00 | 1.00 | 1.00 |
| Lipophilic | 0.99 (0.83–1.19) |
0.94 (0.78–1.13) |
1.23 (0.97–1.56) |
1.22 (0.95–1.56) |
| Hydrophilic | 0.82 (0.56–1.22) |
0.83 (0.56–1.23) |
1.57 (1.05–2.34) |
1.72 (1.15–2.56) |
| Statin potency | ||||
| No use | 1.00 | 1.00 | 1.00 | 1.00 |
| High | 1.00 (0.83–1.22) |
0.94 (0.77–1.15) |
1.20 (0.93–1.56) |
1.22 (0.93–1.60) |
| Medium | 0.95 (0.64–1.42) |
0.96 (0.64–1.68) |
1.72 (1.12–2.62) |
1.87 (1.23–2.86) |
| Low | 0.73 (0.48–1.11) |
0.68 (0.44–1.05) |
1.27 (0.81–1.99) |
1.16 (0.71–1.89) |
All analyses were stratified by WHI trial, extension study and age group.
Base model was adjusted by age.
Multivariable model adjusted for age, BMI, ethnicity, smoking, education, current medical provider, baseline HT use, baseline HT duration.